Search clinical trials for: Chloride Channel Agonists

Total 24024 results

Medical University of South Carolina
Vertex Pharmaceuticals Incorporated

Completed

An Efficacy and Safety Study of Ivacaftor in Patients With Cystic Fibrosis and Two Splicing Mutations

Cystic Fibrosis
Sucampo Pharma Americas, LLC
Sucampo AG

Completed

Evaluation of the Safety of Lubiprostone in Pediatric Participants Aged ≥ 6 Years to < 18 Years With Functional Constipation

Constipation - Functional

United States
Vertex Pharmaceuticals Incorporated
Cystic Fibrosis Foundation

Completed

Study of the Effect of Ivacaftor on Lung Clearance Index in Subjects With Cystic Fibrosis and the G551D Mutation

Cystic Fibrosis

United Kingdom, United States, Canada
Anchen Pharmaceuticals, Inc
Novum Pharmaceutical Research Services

Completed

Evaluation of Clinical Equivalence Between Two Lubiprostone Products

Chronic Idiopathic Constipation

United States
Baylor College of Medicine
University of South Florida

Completed

Amitiza in Constipation Associated With PD (Parkinson's Disease) (AMITIZA)

Parkinson's Disease

United States
Children's Hospital of Philadelphia
Vertex Pharmaceuticals Incorporated

Completed

Ivacaftor Treatment in 4 Month to 2 Year Old CF Subjects

Cystic Fibrosis

United States
University of Alabama at Birmingham
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); Vertex...

Withdrawn

The Multicenter Topic Trial

Chronic Obstructive Pulmonary Disease
Mallinckrodt
Takeda; Sucampo Pharma Americas, LLC; Sucampo AG

Completed

Pharmacodynamic, Pharmacokinetic, and Tolerability Study of a Liquid Form of Lubiprostone in Adult Subjects With Chronic Idiopathic Constipation

Chronic Idiopathic Constipation

United States
Mayo Clinic
Arizona State University; Takeda Pharmaceuticals North America, Inc.

Completed

Intestinal Microecology in Chronic Constipation

Irritable Bowel Syndrome | Other Constipation

United States
Sucampo Pharma Americas, LLC
Sucampo Pharmaceuticals, Inc.

Completed

Efficacy and Safety of Lubiprostone in Patients With Irritable Bowel Syndrome With Constipation

Irritable Bowel Syndrome | Constipation
Sucampo Pharma Americas, LLC
Takeda

Completed

Efficacy and Safety of Lubiprostone in Patients With Irritable Bowel Syndrome With Constipation

Irritable Bowel Syndrome With Constipation
Texas Tech University Health Sciences Center, El...
Takeda Pharmaceuticals North America, Inc.

Completed

Lubiprostone Effect on Gastrointestinal Tract Transit Times Measured by Smartpill in Patients With Chronic Constipation

Chronic Idiopathic Constipation

United States
Dr. Reddy's Laboratories Limited
Parexel

Completed

Evaluation of Clinical Equivalence Between Two Lubiprostone Products in the Treatment of Chronic Idiopathic Constipation

Chronic Idiopathic Constipation

United States
Sucampo Pharma Americas, LLC
Sucampo AG; Sucampo Pharmaceuticals, Inc.

Completed

Evaluation of the Bioequivalence of Sprinkle and Capsule Formulations of Lubiprostone, as Compared to Placebo

Chronic Idiopathic Constipation

United States
Sucampo Pharma Americas, LLC
Sucampo Pharmaceuticals, Inc.

Completed

Safety and Efficacy of Lubiprostone in Pediatric Patients With Constipation

Constipation

United States
Takeda

Completed

Lubiprostone for Treatment of Chronic Idiopathic Constipation

Chronic Idiopathic Constipation

Korea, Republic of
University of Alabama at Birmingham

Completed

TOPIC Trial for COPD

Chronic Obstructive Pulmonary Disease

United States
Sucampo Pharma Americas, LLC
Takeda

Completed

Lubiprostone for Children With Constipation

Constipation - Functional

United States, United Kingdom, Netherlands, Poland, Belgium, France, Canada
University of Alabama at Birmingham

Completed

Evaluation of Ivacaftor in Patients Using Ataluren for Nonsense Mutations

Cystic Fibrosis

United States
Takeda

Completed

Lubiprostone for Chronic Idiopathic Constipation Treatment

Constipation

Mexico
Takeda

Completed

Lubiprostone for the Treatment of Chronic Idiopathic Constipation

Constipation

Russian Federation
Vertex Pharmaceuticals Incorporated

Approved for marketing

VX-770 Expanded Access Program

Cystic Fibrosis
Cedars-Sinai Medical Center
Takeda Pharmaceuticals North America, Inc.

Completed

Effect of Lubiprostone on Small Bowel Contractions in Female Patients With Constipation Irritable Bowel Syndrome (C-IBS)

Constipation-predominant Irritable Bowel Syndrome

United States
Vertex Pharmaceuticals Incorporated

Completed

Study of VX-770 in Subjects With Moderate Hepatic Impairment and in Matched Healthy Subjects

In Development for Cystic Fibrosis

Czech Republic, Slovakia
Vertex Pharmaceuticals Incorporated

Completed

A Study to Evaluate the Safety of Long-term Ivacaftor Treatment in Subjects With Cystic Fibrosis Who Are Less Than 24 Months of Age at Treatment Initiation and Have an Approved Ivacaftor-Responsive Mutation

Cystic Fibrosis

United States, Canada, Australia, Ireland, Germany, United Kingdom
University of Alabama at Birmingham

Withdrawn

VX-770 for the Treatment of Chronic Bronchitis

Chronic Bronchitis

United States
University of Alabama at Birmingham

Recruiting

Personalized Theratyping Trial

Cystic Fibrosis

United States
Assistance Publique - Hôpitaux de Paris
Societe Francaise de la Mucoviscidose; Effi-Stat

Completed

Real-life Follow-up of Cystic Fibrosis Patients Treated With Ivacaftor+Lumacaftor (Orkambi*) (ORKAMBI)

Cystic Fibrosis

France
Vertex Pharmaceuticals Incorporated
Cystic Fibrosis Foundation

Completed

Study of Ivacaftor in Cystic Fibrosis Subjects 2 Through 5 Years of Age With a CFTR Gating Mutation

Cystic Fibrosis

United States, United Kingdom, Canada
Vertex Pharmaceuticals Incorporated
Cystic Fibrosis Foundation

Completed

Study of the Effect of VX-770 on Hyperpolarized Helium-3 Magnetic Resonance Imaging in Subjects With Cystic Fibrosis and the G551D Mutation

Cystic Fibrosis

United States
Vertex Pharmaceuticals Incorporated
Cystic Fibrosis Foundation

Completed

Rollover Study of Ivacaftor in Subjects With Cystic Fibrosis and a Non G551D CFTR Mutation (KONTINUE)

Cystic Fibrosis

United States, France, Belgium, United Kingdom
Vertex Pharmaceuticals Incorporated
Cystic Fibrosis Foundation

Completed

Roll-Over Study of Ivacaftor in Cystic Fibrosis Pediatric Subjects With a CF Transmembrane Conductance Regulator Gene (CFTR) Gating Mutation

Cystic Fibrosis

United States, United Kingdom, Canada
Vertex Pharmaceuticals Incorporated
Cystic Fibrosis Foundation

Completed

Study of Ivacaftor in Cystic Fibrosis Subjects Aged 12 Years and Older With the G551D Mutation (STRIVE)

Cystic Fibrosis

United States, Canada, Australia, Ireland, France, United Kingdom, Germany, Czech Republic
Vertex Pharmaceuticals Incorporated
Cystic Fibrosis Foundation

Completed

Study of Ivacaftor in Cystic Fibrosis Subjects Aged 6 to 11 Years With the G551D Mutation (ENVISION)

Cystic Fibrosis

United States, Australia, Canada, France, Germany, Ireland, United Kingdom
University of North Carolina, Chapel Hill
Takeda

Completed

Lubiprostone Effects on Visceral Pain Sensitivity

Irritable Bowel Syndrome

United States
Vertex Pharmaceuticals Incorporated

Completed

Observational Study of Outcomes in Cystic Fibrosis Patients With Selected Gating Mutations on a CFTR Allele (The VOCAL Study) (VOCAL)

Cystic Fibrosis

Netherlands, Italy, United Kingdom
Vertex Pharmaceuticals Incorporated

Terminated

A Study to Evaluate Efficacy and Safety of Ivacaftor in Subjects With Cystic Fibrosis Aged 3 Through 5 Years Who Have a Specified CFTR Gating Mutation

Cystic Fibrosis

United Kingdom, Canada, Australia
Dartmouth-Hitchcock Medical Center
Takeda Pharmaceuticals North America, Inc.

Completed

Effects of Lubiprostone on Gastric Function in Patients With Chronic Idiopathic Constipation

Chronic Idiopathic Constipation

United States
Vertex Pharmaceuticals Incorporated

Completed

A Phase 3 Rollover Study of Lumacaftor in Combination With Ivacaftor in Subjects 12 Years and Older With Cystic Fibrosis

Cystic Fibrosis, Homozygous or Heterozygous for the F508del-CFTR Mutation

United States, France, United Kingdom, Germany, Spain, Belgium, Canada, Australia, Netherlands, Denmark, Czech Republic, Italy, Austria, Ireland, Sweden
Vertex Pharmaceuticals Incorporated
Cystic Fibrosis Foundation

Completed

Rollover Study of VX-770 in Cystic Fibrosis Subjects

Cystic Fibrosis

United States, France, United Kingdom, Germany, Canada, Czech Republic, Ireland, Australia
Vertex Pharmaceuticals Incorporated
Cystic Fibrosis Foundation

Completed

Study of Ivacaftor in Subjects With Cystic Fibrosis (CF) Who Have the R117H-CF Transmembrane Conductance Regulator (CFTR) Mutation (KONDUCT) (KONDUCT)

Cystic Fibrosis

United States, United Kingdom
University of Arkansas
Takeda Pharmaceuticals North America, Inc.

Completed

Short Term Safety and Efficacy of Lubiprostone in Adults With Cystic Fibrosis

Constipation | Cystic Fibrosis

United States
Sucampo Pharma Americas, LLC
Sucampo AG

Completed

Lubiprostone in Children With Functional Constipation

Constipation - Functional

United States, United Kingdom, Canada, Netherlands, Poland, Belgium, France
Sucampo Pharma Americas, LLC
Takeda; Sucampo AG

Terminated

Evaluation of the Efficacy and Safety of Lubiprostone in Adults With Mixed or Unsubtyped Irritable Bowel Syndrome

Irritable Bowel Syndrome

United States
Texas Tech University Health Sciences Center, El...

Completed

Lubiprostone and Mucus Secretion in Patients With Chronic Constipation

Constipation

United States
Vertex Pharmaceuticals Incorporated
Cystic Fibrosis Foundation

Completed

An Ocular Safety Study of Ivacaftor-Treated Pediatric Patients 11 Years of Age or Younger With Cystic Fibrosis

Cystic Fibrosis

United States
Vertex Pharmaceuticals Incorporated
Cystic Fibrosis Foundation

Terminated

Study of Ivacaftor in Cystic Fibrosis Subjects Aged 12 Years and Older Homozygous for the F508del-CFTR Mutation (DISCOVER)

Cystic Fibrosis

United States
Vertex Pharmaceuticals Incorporated

Completed

Study of VX-770 on Desipramine

In Development for Cystic Fibrosis

United States
Vertex Pharmaceuticals Incorporated

Completed

A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Ivacaftor in Subjects With Cystic Fibrosis Who Are Less Than 24 Months of Age and Have an Ivacaftor-Responsive CFTR Mutation

Cystic Fibrosis

United States, Canada, United Kingdom, Australia, Ireland
Vertex Pharmaceuticals Incorporated

Completed

A Study to Evaluate Efficacy of Ivacaftor in Subjects With Cystic Fibrosis Who Have a 3849 + 10KB C→T or D1152H CFTR Mutation

Cystic Fibrosis

Israel

Search clinical trials for: Chloride Channel Agonists

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Malta

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations